Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 41 references it cites were found in a registry or an index, and 15 are not checked yet; 8 of the 37 sources its claims cite were checked for support.

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Open access

Abstract

Background: Chronic kidney disease (CKD) is a common complication of type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and lower body weight in people with T2D, and some reduce the risk of cardiovascular (CV) events in those with high CV risk. GLP-1RAs might also have kidney-protective effects. We report the design and baseline data for FLOW (NCT03819153), a trial investigating the effects of semaglutide, a once-weekly (OW) GLP-1RA, on kidney outcomes in participants with CKD and T2D. Methods: FLOW is a randomised, double-blind, parallel-group, multinational, phase 3b trial. Participants with T2D, estimated glomerular filtration rate (eGFR) ≥50‒≤75 ml/min/1.73 m2 and urine albumin:creatinine ratio (UACR) >300‒<5000 mg/g or eGFR ≥25‒<50 ml/min/1.73 m2 and UACR >100‒<5000 mg/g were randomised 1:1 to OW semaglutide 1.0 mg or matched placebo, with renin–angiotensin–aldosterone system blockade (unless not tolerated/contraindicated). The composite primary endpoint is time to first kidney failure (persistent eGFR <15 ml/min/1.73 m2 or initiation of chronic kidney replacement therapy), persistent ≥50% reduction in eGFR or death from kidney or CV causes. Results: Enrolled participants (N = 3534) had a baseline mean age of 66.6 years [standard deviation (SD) 9.0], haemoglobin A1c of 7.8% (SD 1.3), diabetes duration of 17.4 years (SD 9.3), eGFR of 47.0 ml/min/1.73 m2 (SD 15.2) and median UACR of 568 mg/g (range 2‒11 852). According to Kidney Disease: Improving Global Outcomes guidelines categorisation, 68.2% were at very high risk for CKD progression. Conclusion: FLOW will evaluate the effect of semaglutide on kidney outcomes in participants with CKD and T2D, and is expected to be completed in late 2024.

Verified 2026-10-05 · 15 references not checked yet

Overview

CoChat Summary

TL;DR

FLOW is a randomised, double-blind, phase 3b kidney outcomes trial testing once-weekly semaglutide 1.0 mg versus placebo in 3534 adults with type 2 diabetes and chronic kidney disease. This report describes the rationale, design, and baseline characteristics; efficacy results are not yet available.

Key findings

  • FLOW enrolled 3534 participants across 418 sites in 28 countries; baseline mean age was 66.6 years (SD 9.0), 69.7% were male, and 65.7% were white.
  • Baseline kidney burden was substantial: mean eGFR 47.0 ml/min/1.73 m² (SD 15.2), median UACR 568 mg/g (range 2–11 852), 68.4% had macroalbuminuria, and 68.2% were classified as very high risk for CKD progression by KDIGO criteria.
  • Baseline diabetes and cardiovascular burden included mean HbA1c 7.8% (SD 1.3), mean diabetes duration 17.4 years (SD 9.3), BMI 32.0 kg/m² (SD 6.3), 52.0% with previous cardiovascular disease, and 19.1% with previous heart failure.
  • At baseline, 95.3% were receiving RAAS inhibitors, 15.5% SGLT2is, 61.5% insulin, and 51.6% metformin; the trial was powered to detect a 20% relative risk reduction (HR 0.8) for the primary composite endpoint, requiring 854 events.

Methods

  • Randomised, double-blind, parallel-group, multinational phase 3b trial; adults with type 2 diabetes and CKD were eligible if they had eGFR ≥50–≤75 ml/min/1.73 m² and UACR >300–<5000 mg/g, or eGFR ≥25–<50 ml/min/1.73 m² and UACR >100–<5000 mg/g, on stable maximum labelled or tolerated RAAS blockade unless contraindicated or not tolerated.
  • Participants were randomised 1:1 to once-weekly subcutaneous semaglutide 1.0 mg or matched placebo, stratified by SGLT2i use at baseline; the primary composite endpoint was time to first kidney failure, persistent ≥50% reduction in eGFR, or death from kidney or cardiovascular causes.
  • Baseline data are reported descriptively from 3534 randomised participants using central laboratory eGFR and UACR assessments; the event-driven trial uses a group sequential design, intention-to-treat estimand, and stratified Cox proportional hazards model.

Limitations

  • The paper states that eligibility could be based on historical laboratory values, but baseline data came from central laboratory assessments, resulting in a small number of participants not fulfilling all inclusion criteria at that specific visit.
  • The paper states that the mechanism of kidney protection with GLP-1RAs is not fully elucidated, and that prior kidney data from cardiovascular outcomes trials are hypothesis generating because of low CKD prevalence and secondary endpoints.
  • Evident from the text: this report provides rationale, design, and baseline characteristics only; no FLOW efficacy or safety outcome results are reported, so treatment effects on kidney outcomes remain unknown.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/ndt/gfad009

Cites

25 of 40 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Graphical Abstract
Graphical Abstract CC BY-NC · PubMed Central
Figure 1: Results of exploratory kidney analyses from GLP-1RA CV outcomes trials. *P < .05. †Defined as doubling of serum creatinine in LEADER, SUSTAIN 6 and ELIXA and sustained eGFR decline of ≥30% in REWIND. Direct comparisons not possible due to differing study designs. Secondary kidney composite endpoints were new-onset persistent macroalbuminuria/very high albuminuria, persistent doubling of the serum creatinine or end-stage kidney disease in LEADER; first occurrence of new macroalbuminuria/very high albuminuria (UACR >33.9 mg/mmol), a sustained decline in eGFR of ≥30% or chronic KRT in REWIND; new or worsening nephropathy (defined as persistent macroalbuminuria/very high albuminuria, persistent doubling of serum creatinine and a creatinine clearance of <45 ml/min/1.73 m2 or the need for continuous KRT) in SUSTAIN 6; a 40% decline in eGFR, KRT, kidney death or incident macroalbuminuria/very high albuminuria in EXSCEL; and incident macroalbuminuria (UACR >33.9 mg/mmol) plus an increase in UACR of ≥30% from baseline, sustained decrease in eGFR of ≥40% for ≥30 days, renal replacement therapy for ≥90 days and sustained eGFR <15 ml/min/1.73 m2 for ≥30 days in AMPLITUDE-O [6, 7, 10, 13, 38, 43]. exenatide ER, exenatide extended release; KRT, kidney replacement therapy; NR, not reported.
Figure 1: Results of exploratory kidney analyses from GLP-1RA CV outcomes trials. *P < .05. †Defined as doubling of serum creatinine in LEADER, SUSTAIN 6 and ELIXA and sustained eGFR decline of ≥30% in REWIND. Direct comparisons not possible due to differing study designs. Secondary kidney composite endpoints were new-onset persistent macroalbuminuria/very high albuminuria, persistent doubling of the serum creatinine or end-stage kidney disease in LEADER; first occurrence of new macroalbuminuria/very high albuminuria (UACR >33.9 mg/mmol), a sustained decline in eGFR of ≥30% or chronic KRT in REWIND; new or worsening nephropathy (defined as persistent macroalbuminuria/very high albuminuria, persistent doubling of serum creatinine and a creatinine clearance of <45 ml/min/1.73 m2 or the need for continuous KRT) in SUSTAIN 6; a 40% decline in eGFR, KRT, kidney death or incident macroalbuminuria/very high albuminuria in EXSCEL; and incident macroalbuminuria (UACR >33.9 mg/mmol) plus an increase in UACR of ≥30% from baseline, sustained decrease in eGFR of ≥40% for ≥30 days, renal replacement therapy for ≥90 days and sustained eGFR <15 ml/min/1.73 m2 for ≥30 days in AMPLITUDE-O [6, 7, 10, 13, 38, 43]. exenatide ER, exenatide extended release; KRT, kidney replacement therapy; NR, not reported.CC BY-NC · PubMed Central
Figure 2: FLOW trial design. *Stratified by SGLT-2i use (yes/no). EOT, end of treatment; N, number of participants; W, week.
Figure 2: FLOW trial design. *Stratified by SGLT-2i use (yes/no). EOT, end of treatment; N, number of participants; W, week.CC BY-NC · PubMed Central
Figure 3: Map of trial site locations.
Figure 3: Map of trial site locations.CC BY-NC · PubMed Central
Figure 4: KDIGO risk categories among FLOW participants. Data are n (%) for each category. To facilitate recruitment to the FLOW trial and increase generalisability of the outcomes by reflecting typical clinical practice, eligibility in terms of laboratory results could be based on historical values. Adapted from the KDIGO Diabetes Work Group, 2020 [3].
Figure 4: KDIGO risk categories among FLOW participants. Data are n (%) for each category. To facilitate recruitment to the FLOW trial and increase generalisability of the outcomes by reflecting typical clinical practice, eligibility in terms of laboratory results could be based on historical values. Adapted from the KDIGO Diabetes Work Group, 2020 [3].CC BY-NC · PubMed Central

Verification

Claims the paper makes

4 Valid · 1 Not valid · 17 Not checked · 57 Own results and interpretations

25 more claims

Create a free account to see all 79 claims and to verify the 29 references still open.

See all claims — free account
  • It may state two separate claims as one. 12
  • Probably not a substantial claim. 39

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. International Diabetes Federation, Diabetes Atlas

Cited by

See all 257

Metadata

Authors
Rossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., Mersebach, H., Perkovic, V., Tuttle, K., & Pratley, R.
Affiliations
  • University of Copenhagen (DK)
  • Novo Nordisk (Denmark) (DK)
  • University of Chicago (US)
  • Novo Nordisk A/S , Søborg , Denmark
  • Stanford Medicine (US)
  • Outpatients Clinic, KfH Kidney Center , München , Germany
  • UNSW Sydney (AU)
  • University of Washington (US)
  • AdventHealth Orlando (US)
Corresponding author
Rossing, Peter
Venue
Nephrology Dialysis Transplantation
Published
2023-01-18
Volume
38
Issue
9
Pages
2041-2051
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W4317213523
Cited by
242
References
41
Citations by year
2026: 37 · 2025: 52 · 2024: 107 · 2023: 46
FWCI
46.96
Type
journal article
Language
en
Open access
Locations
  • Nephrology Dialysis Transplantation (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
semaglutide, type 2 diabetes, chronic kidney disease, renal failure, GLP-1 receptor agonists, FLOW trial, estimated glomerular filtration rate, albuminuria, renin-angiotensin-aldosterone system blockade, renal outcomes, trial design, baseline characteristics, cardiovascular outcomes
MeSH terms
Semaglutide, Aged, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Kidney, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. https://app.cochat.ai/papers/10.1093/ndt/gfad009
The paper
Rossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., Mersebach, H., Perkovic, V., Tuttle, K., & Pratley, R. (2023). The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfad009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.